Select a medication above to begin.
Byfavo
remimazolam
Black Box Warnings .
Appropriate Use
only personnel trained in procedural sedation administration, and not involved in conduct of diagnostic/therapeutic procedure should administer remimazolam, and must be trained in detection and management of airway obstruction, hypoventilation, apnea, including maintenance of patent airway, supportive ventilation, cardiovascular resuscitation; associated with hypoxia, bradycardia, hypotension; continuously monitor vital signs duration sedation and through recovery period; resuscitative drugs, appropriate equipment for bag/valve/mask assisted ventilation must be available
Risks from Concomitant Opioid and Other Sedative-Hypnotic Use
concomitant benzodiazepine use with opioids may result in profound sedation, respiratory depression, coma, and death; sedative effect of IV remimazolam may be accentuated by concomitant CNS depressants, including other benzodiazepines and propofol; monitor continuously for respiratory depression and depth of sedation
Adult Dosing .
Dosage forms: INJ
procedural sedation induction
- [5 mg IV x1]
- Info: for procedures lasting 30min or less; give 2.5-5 mg IV x1 in American Society of Anesthesiologists physical status III-IV patients
procedural sedation maintenance
- [2.5 mg IV q2min prn]
- Info: for procedures lasting 30min or less; give 1.25-2.5 mg IV q2min prn in American Society of Anesthesiologists physical status III-IV patients
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- mild-moderate impairment: not defined, caution advised; severe impairment: consider decr. usual frequency, titrate gradually to effect
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.